Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
REFERENCE CODE GDME0208MAR | PUBLICATION DATE DECEMBER 2014
NUCLEAR IMAGING- PET AND SPECT EQUIPMENT - GLOBAL ANALYSIS AND MARKET FORECASTS
Nuclear Imaging- PET and SPECT Equipment - Global Analysis and Market Forecasts 2 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
NUCLEAR IMAGING- PET AND SPECT EQUIPMENT - GLOBAL ANALYSIS AND MARKET FORECASTS
Executive Summary
Nuclear Imaging Market Overview
GlobalData estimates the global nuclear imaging
market to have been worth $1.77 billion in 2012
and $1.83 billion in 2013. GlobalData estimates
that this market will be worth $2.2 billion in 2020,
increasing at a Compound Annual Growth Rate
(CAGR) of 3.3% during the period of 2014 to 2020.
The key drivers for the global nuclear imaging
market are:
Aging population and increasing disease
prevalence
Increasing referring physician awareness
Increasing defensive medicine
Increasing patient awareness
Increasing self-referral behavior
Increasing implementation of comparative
effectiveness research
Improved accreditation of imaging facilities
Availability of new imaging reagents
Increasing demand for cancer diagnoses
Increasing demand for imaging-based
companion diagnostics
Replacement of positron emission tomography
(PET)/computed tomography (CT) by
PET/magnetic resonance imaging (MRI)
Replacement of single-photon emission
computed tomography (SPECT)-only systems
The key barriers of the global nuclear imaging
market are:
Legislation affecting reimbursements
The lobbying efforts of medical insurance
companies and consequent reduction in the
number of procedures performed
Greater scrutiny of electronic medical records
by healthcare payers, leading to a reduction in
the number of procedures performed.
Increased use of appropriateness criteria,
resulting in reduced examinations
Practice guidelines reducing unnecessary
procedures
Loss of nuclear medicine skills
High cost of instruments and reagents
Supply difficulties and increasing cost of radio-
pharmaceuticals
Medical Device Excise tax increasing
development costs
Hospital consolidation reducing the number of
scanning facilities
The nuclear imaging market is a moderately
growing market with a 2014-2020 CAGR of 3.3%
globally. It is a mature sector of the diagnostic
imaging market; continued growth is expected
along with continued technological developments
and the emerging markets’ acceptance of
products.
Nuclear Imaging- PET and SPECT Equipment - Global Analysis and Market Forecasts 3 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
NUCLEAR IMAGING- PET AND SPECT EQUIPMENT - GLOBAL ANALYSIS AND MARKET FORECASTS
Executive Summary
Below mentioned Table presents the key metrics of
the nuclear imaging industry during 2012-2020.
Nuclear Imaging Key Metrics: Key Events and Pipeline Assessment
2012 Market Sales ($m)
US $1,216.4m
5EU $212.6m
APAC $286.1m
Brazil $55.4m
Total $1,770.6m
Key Events (2012–2020) Level of Impact
Patient Protection and Affordable Care Act of 2010 ↑↑↑↑↑↑
Affordable Care Act of 2011 ↑↑↑↑↑↑
Approval by European Council on new EU Medical Device Regulations in 2015 ↑↑↑↑
Implementation of new EU Medical Device Regulations during 2018 to 2020 ↑↑↑↑
Reform of CFDA Medical Device Regulation in 2014 ↑↑
Conclusion of Philips PET Alpha Ring trials in 2014 ↑
GE Healthcare PET/CT & PET/MRI Comparison Trial 2014 ↑↑
Pipeline and Competitive Landscape Assessment
Total pipeline products profiled 11
Total companies profiled 26
2020 Market Sales ($m)
US $1,165.6m
5EU $308.2m
APAC $631.5m
Brazil $91.2m
Total $2,196.3m Source: GlobalData, primary research interviews with leading nuclear medicine specialist in 10 markets (US, France, Germany, Italy, Spain, UK, Japan, Brazil, China, and India). 5EU = France, Germany, Italy, Spain, and UK; APAC = Asia-Pacific (Japan, China, and India)
US Dominates the Nuclear Imaging Market
In 2012, the US dominated the global nuclear
imaging market, accounting for 69% of sales
globally. The market is dominated by three
companies: the market leader is Philips Healthcare
with around 35% of the market by revenue,
followed closely by GE Healthcare with around
33% of the market, and Siemens Healthcare at just
under 30%.
Global Nuclear Imaging Market in 2012
United States69%
APAC16%
5EU12%
Brazil3%
Source: GlobalData APAC = Asia Pacific; 5EU = France, Germany, Italy, Spain, and UK
Demand for Nuclear Imaging in US to Become Static
The US is the largest market for nuclear imaging,
in terms of the number of systems sold and the
number of procedures carried out. However, a
period of a rapid increase in procedures in the US,
particularly PET and PET/CT, has led to measures
to reduce the number of procedures that can be
reimbursed, and thus reduce the demand for
Nuclear Imaging- PET and SPECT Equipment - Global Analysis and Market Forecasts 4 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
NUCLEAR IMAGING- PET AND SPECT EQUIPMENT - GLOBAL ANALYSIS AND MARKET FORECASTS
Executive Summary
nuclear imaging systems. Prior to healthcare
reform, the major threat to the US nuclear imaging
market was the limited supply of
radiopharmaceuticals.
APAC to Foster Future Growth
APAC economies, especially China and Japan, will
continue to provide immense opportunities for
increasing sales within the global nuclear imaging
market. GlobalData projects that Japan will
increase its market share by 75% and that China
will almost double its market share.
GlobalData expects that the growth of sales in
China will be attributed in part to the sale of more
PET/CT and SPECT/CT systems, whereas in
Japan, growth will be due to increasing demand for
SPECT/CT and PET/MRI systems.
Future Outlook
The economic downturn has been a continued
concern within the whole of the diagnostic imaging
market. Indeed, the high cost of nuclear imaging
equipment and procedures has made the nuclear
imaging market more susceptible to the downturn.
The market growth for nuclear imaging in the US
and EU is heavily dependent on the replacement of
already existing systems because, as is the case in
most of the developed countries, the capacity for
new installations is limited. As the US and EU
economies recover, it can be expected that the
equipment will be replaced.
However, at this point in time, the key opinion
leaders (KOLs) that GlobalData interviewed for this
report indicated that not all equipment is replaced
at the end of the average product lifecycle,
negatively affecting sales in the US and EU
markets.
The rising prevalence of disease, an aging
population, and a growing global population will act
as major drivers of the increased use of nuclear
imaging. However, cost-containment measures
implemented by healthcare authorities will affect
which nuclear imaging technologies are favored.
What do Physicians Think?
GlobalData interviewed a number of KOLs in the
nuclear imaging setting; they discussed a wide
variety of points and concerns, providing insight
into clinicians’ view of the technologies found in
nuclear imaging, both existing and future. In
addition, the KOLs provided viewpoints into the
healthcare regimes related to nuclear imaging, and
how these might affect access to imaging.
Physicians provided insight into the major imaging
modalities, PET/CT, SPECT/CT and PET/MRI.
PET/CT will eventually replace many SPECT/CT
procedures, but this is dependent upon progress in
developing new radiotracer compounds.
“Whenever a tracer appears that can replace
SPECT/CT by PET/CT, SPECT/CT will tend to
disappear, but this will be a very slow [process]….
In the next ten years probably the number of
PET/CT examinations will [double] and those by
SPECT/CT [will halve].”
EU KOL
Nuclear Imaging- PET and SPECT Equipment - Global Analysis and Market Forecasts 5 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
NUCLEAR IMAGING- PET AND SPECT EQUIPMENT - GLOBAL ANALYSIS AND MARKET FORECASTS
Executive Summary
But there is still space for SPECT, provided that
the major manufacturer promotes it as a technique.
“[It’s] only very recently that manufacturers have
started promoting SPECT as a competitive tool. I’m
surprised; I don’t know why it took so long. Maybe
it’s because they were pretty overwhelmed in their
expanding PET market.”
EU KOL
While SPECT is well-established, SPECT/CT still
struggles to be reimbursed.
“Reimbursements are down, and specifically
talking about nuclear medicine, we have been
doing SPECT but there isn’t any reimbursement for
SPECT/CT; for those hybrid modalities… there
isn’t a separate reimbursement, and that is where
people are providing a service when needed and
doing SPECT/CTs, but not getting any additional
remuneration for these services provided.”
US KOL
Physicians remain to be convinced that PET/MRI
will revolutionize nuclear imaging.
“The real question is whether, given the expense
and the complexity, if [PET/MRI] ever gets out of
the academic medical centers and into general
clinical practice. There hasn’t been an application
that really … justifies the complexity and the added
cost.
US KOL
Stricter policies by insurance companies are
affecting patient access to nuclear imaging.
“More and more insurance companies are using
appropriateness criteria strictly, and regulating
access to PET/CT procedures especially the
cancer population….”
US KOL
US healthcare reforms may eventually increase
patient access to nuclear imaging, but may not
necessarily benefit the physician.
“As the effects of the Affordable Care Act kick
in…It may balance out where the volumes are
increasing, because more people have insurance,
but the reimbursements are going down.”
US KOL
Changes in reimbursement policies, leading to a
reduction in the number of nuclear imaging
procedures, are affecting hiring at hospitals and
leading to a potential loss of skills.
“These days they are hiring people with skills in the
rest of radiology, such as CT, MR, and not just
nuclear medicine, so that’s the reason why nuclear
medicine jobs are shrinking.”
US KOL
Nuclear Imaging- PET and SPECT Equipment - Global Analysis and Market Forecasts 6 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
NUCLEAR IMAGING- PET AND SPECT EQUIPMENT - GLOBAL ANALYSIS AND MARKET FORECASTS
Executive Summary
Ultimately, changes in reimbursement affecting the
career prospects of specialist physicians may also
result in the dilution of nuclear imaging skills might
affect the effectiveness of diagnosing disease.
“Radiologists who read PET/CT studies are also
not certified….. only have four months of nuclear
medicine, so imagine the life of a cancer patient or
a management position dependent on a person
who has had only four months of training in that
specialty.”
US KOL
Nuclear Imaging- PET and SPECT Equipment - Global Analysis and Market Forecasts 7 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
NUCLEAR IMAGING- PET AND SPECT EQUIPMENT - GLOBAL ANALYSIS AND MARKET FORECASTS
1 Table of Contents
1 Table of Contents ....................................................................................................................... 7
1.1 List of Tables .................................................................................................................... 14
1.2 List of Figures ................................................................................................................... 18
2 Introduction ............................................................................................................................... 21
2.1 Catalyst ............................................................................................................................. 21
2.2 Related Reports ................................................................................................................ 22
3 Industry Overview ..................................................................................................................... 23
3.1 Nuclear Imaging Techniques ............................................................................................. 23
3.1.1 Positron Emission Tomography ..................................................................................... 23
3.1.2 Single-Photon Emission Computed Tomography .......................................................... 25
3.1.3 Planar Scintigraphy ....................................................................................................... 25
3.1.4 Hybrid Imaging .............................................................................................................. 26
3.2 Clinical Applications of Nuclear Imaging Technology ........................................................ 31
3.2.1 Cancer .......................................................................................................................... 31
3.2.2 Cardiology ..................................................................................................................... 33
3.2.3 Neurology ...................................................................................................................... 35
3.2.4 Infection and Inflammation ............................................................................................ 37
3.3 Advantages and Disadvantages of Nuclear Imaging Technologies ................................... 40
3.4 Market Access .................................................................................................................. 41
3.4.1 Product Life Cycle ......................................................................................................... 41
3.4.2 Purchasing Decisions .................................................................................................... 43
3.4.3 Equipment Leasing........................................................................................................ 49
3.4.4 Replacement of PET/CT by PET/MRI............................................................................ 49
3.5 Reimbursement ................................................................................................................. 54
3.5.1 Overview ....................................................................................................................... 54
3.5.2 US ................................................................................................................................. 55
Nuclear Imaging- PET and SPECT Equipment - Global Analysis and Market Forecasts 8 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
NUCLEAR IMAGING- PET AND SPECT EQUIPMENT - GLOBAL ANALYSIS AND MARKET FORECASTS
3.5.3 France ........................................................................................................................... 55
3.5.4 Germany ....................................................................................................................... 57
3.5.5 Italy ............................................................................................................................... 58
3.5.6 Spain ............................................................................................................................. 59
3.5.7 UK ................................................................................................................................. 60
3.5.8 Japan ............................................................................................................................ 61
3.5.9 Brazil ............................................................................................................................. 61
3.5.10 China ............................................................................................................................ 62
3.5.11 India .............................................................................................................................. 63
3.6 Procedure Trends ............................................................................................................. 64
3.6.1 US ................................................................................................................................. 64
3.6.2 France ........................................................................................................................... 67
3.6.3 Germany ....................................................................................................................... 69
3.6.4 Italy ............................................................................................................................... 73
3.6.5 Spain ............................................................................................................................. 75
3.6.6 UK ................................................................................................................................. 77
3.6.7 Japan ............................................................................................................................ 80
3.6.8 Brazil ............................................................................................................................. 82
3.6.9 China ............................................................................................................................ 85
3.6.10 India .............................................................................................................................. 87
3.7 Regulatory Issues/Recalls ................................................................................................. 90
3.8 M&As and Key Partnerships ............................................................................................. 91
3.9 Economic Impact .............................................................................................................. 94
3.9.1 US ................................................................................................................................. 94
3.9.2 Europe .......................................................................................................................... 97
4 Unmet Needs ............................................................................................................................ 98
4.1 Overview ........................................................................................................................... 98
Nuclear Imaging- PET and SPECT Equipment - Global Analysis and Market Forecasts 9 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
NUCLEAR IMAGING- PET AND SPECT EQUIPMENT - GLOBAL ANALYSIS AND MARKET FORECASTS
4.2 Improved Reimbursement for New Techniques ................................................................. 98
4.3 Lack of Binding Clinical Guidelines ................................................................................. 102
4.4 Patient Comfort and Convenience................................................................................... 102
4.5 Reducing Radiation Exposure ......................................................................................... 103
4.6 Improved Scanner Performance ..................................................................................... 105
4.7 Image Processing Software Improvements ..................................................................... 106
4.8 Increased Risk of Artifacts in Hybrid Images ................................................................... 108
4.9 Demand for New Radiotracers ........................................................................................ 109
4.10 Improved Clinical Input into the Design Process ............................................................. 111
5 Market Opportunity Analysis ................................................................................................... 112
5.1 Cheaper, Simpler Nuclear Imaging Devices .................................................................... 112
5.2 SPECT/CT in Developing Countries ................................................................................ 112
5.3 Increased Demand for Teleradiology Services ................................................................ 115
6 Market Drivers and Barriers .................................................................................................... 117
6.1 Driver: Aging Population and Increasing Disease Prevalence ......................................... 117
6.2 Driver: Referring Physician Awareness ........................................................................... 118
6.3 Driver: Defensive medicine ............................................................................................. 119
6.4 Driver: Patient Awareness ............................................................................................... 121
6.5 Driver: Self-Referral ........................................................................................................ 121
6.6 Driver: New Imaging Agents............................................................................................ 122
6.7 Driver: Increasing Demand for Cancer Diagnostic Tests ................................................. 122
6.8 Driver: Companion Diagnostic Testing ............................................................................ 123
6.9 Barrier: Comparative Effectiveness Research ................................................................. 124
6.10 Barrier: Reimbursement Legislation ................................................................................ 126
6.11 Barrier: Increasing Demand for Nuclear Imaging in Developing Markets ......................... 126
6.12 Barrier: Insurance Company Lobbying to Reduce Unnecessary Imaging ....................... 128
6.13 Barrier: Greater Payer Scrutiny of EMRs ......................................................................... 128
Nuclear Imaging- PET and SPECT Equipment - Global Analysis and Market Forecasts 10 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
NUCLEAR IMAGING- PET AND SPECT EQUIPMENT - GLOBAL ANALYSIS AND MARKET FORECASTS
6.14 Barrier: Increased Use of Appropriateness Criteria ......................................................... 129
6.15 Barrier: Practice Guidelines to Reduce Unnecessary Procedures ................................... 131
6.16 Barrier: Imaging Facility Accreditation ............................................................................. 131
6.17 Barrier: Loss of Nuclear Medicine Skills .......................................................................... 132
6.18 Barrier: High Cost of Instruments and Reagents ............................................................. 133
6.19 Barrier: Radiopharmaceutical Cost and Supply Difficulties .............................................. 134
6.20 Barrier: Medical Device Excise Tax ................................................................................. 137
6.21 Barrier: Hospital Consolidation ........................................................................................ 137
7 Competitive Assessment ........................................................................................................ 139
7.1 Overview ......................................................................................................................... 139
7.2 Dedicated PET Systems ................................................................................................. 139
7.2.1 Overview ..................................................................................................................... 139
7.2.2 Product Profile............................................................................................................. 140
7.2.3 SWOT Analysis ........................................................................................................... 141
7.3 PET/CT Systems ............................................................................................................ 141
7.3.1 Overview ..................................................................................................................... 141
7.3.2 Product Profiles ........................................................................................................... 142
7.3.3 SWOT Analysis ........................................................................................................... 144
7.4 PET/MRI Systems ........................................................................................................... 144
7.4.1 Overview ..................................................................................................................... 144
7.4.2 Product Profile............................................................................................................. 146
7.4.3 SWOT Analysis ........................................................................................................... 147
7.5 Dedicated SPECT Systems ............................................................................................ 147
7.5.1 Overview ..................................................................................................................... 147
7.5.2 Product Profile............................................................................................................. 149
7.5.3 SWOT Analysis ........................................................................................................... 150
7.6 SPECT/CT Systems........................................................................................................ 151
Nuclear Imaging- PET and SPECT Equipment - Global Analysis and Market Forecasts 11 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
NUCLEAR IMAGING- PET AND SPECT EQUIPMENT - GLOBAL ANALYSIS AND MARKET FORECASTS
7.6.1 Overview ..................................................................................................................... 151
7.6.2 Product Profile............................................................................................................. 153
7.6.3 SWOT Analysis ........................................................................................................... 154
7.7 PET/Ultrasound and SPECT/Ultrasound Systems .......................................................... 155
7.7.1 Overview ..................................................................................................................... 155
7.7.2 Product Profile............................................................................................................. 155
7.7.3 SWOT Analysis ........................................................................................................... 156
8 Pipeline Assessment............................................................................................................... 157
8.1 Overview ......................................................................................................................... 157
8.2 Pipeline by Phases in Development ................................................................................ 158
8.3 Product Profiles ............................................................................................................... 158
8.3.1 Brain Biosciences CerePET ........................................................................................ 158
8.3.2 ECORAD Dual Modality Imager .................................................................................. 160
8.3.3 FMI Technologies ScintiStar PET/CT .......................................................................... 161
8.3.4 IntraMedical Imaging Marginator Beta Camera ........................................................... 163
8.3.5 INSERT SPECT/MRI ................................................................................................... 164
8.3.6 Nucare/Zecotek Photonics New Generation PET Scanning Device ............................. 167
8.3.7 Philips Healthcare PET Alpha Ring Detector ............................................................... 168
8.3.8 Photo Diagnostic Systems NeuroPET/CT ................................................................... 169
8.3.9 SynchroPET Breast PET/MRI ..................................................................................... 170
8.3.10 SynchroPET Wrist Scanner ......................................................................................... 171
8.3.11 SurgicEye SPECT Hybrid ............................................................................................ 172
9 Clinical Trials to Watch ........................................................................................................... 174
9.1 Overview ......................................................................................................................... 174
9.2 Clinical Trial Profiles........................................................................................................ 174
10 Current and Future Players ..................................................................................................... 177
10.1 Overview ......................................................................................................................... 177
Nuclear Imaging- PET and SPECT Equipment - Global Analysis and Market Forecasts 12 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
NUCLEAR IMAGING- PET AND SPECT EQUIPMENT - GLOBAL ANALYSIS AND MARKET FORECASTS
10.2 Trends in Corporate Strategy .......................................................................................... 177
10.3 Company Profiles ............................................................................................................ 178
10.3.1 DDD-Diagnostic .......................................................................................................... 178
10.3.2 Digirad......................................................................................................................... 180
10.3.3 GE Healthcare............................................................................................................. 184
10.3.4 GVI Medical Devices ................................................................................................... 189
10.3.5 Mediso Medical Imaging Systems ............................................................................... 191
10.3.6 NeuroLogica ................................................................................................................ 193
10.3.7 Neusoft Medical Systems ............................................................................................ 196
10.3.8 NuCare Medical Systems ............................................................................................ 199
10.3.9 Oncovision .................................................................................................................. 201
10.3.10 Philips Healthcare ....................................................................................................... 203
10.3.11 Shimadzu .................................................................................................................... 210
10.3.12 Siemens Healthcare .................................................................................................... 215
10.3.13 SurgicEye .................................................................................................................... 221
10.3.14 Toshiba Medical .......................................................................................................... 224
10.3.15 Other Companies ........................................................................................................ 229
11 Market Outlooks...................................................................................................................... 232
11.1 Company Market Share Analysis .................................................................................... 232
11.1.1 Global Overview .......................................................................................................... 232
11.1.2 US ............................................................................................................................... 233
11.1.3 France ......................................................................................................................... 233
11.1.4 Germany ..................................................................................................................... 234
11.1.5 Italy ............................................................................................................................. 235
11.1.6 Spain ........................................................................................................................... 236
11.1.7 UK ............................................................................................................................... 237
11.1.8 Japan .......................................................................................................................... 238
Nuclear Imaging- PET and SPECT Equipment - Global Analysis and Market Forecasts 13 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
NUCLEAR IMAGING- PET AND SPECT EQUIPMENT - GLOBAL ANALYSIS AND MARKET FORECASTS
11.1.9 Brazil ........................................................................................................................... 239
11.1.10 China .......................................................................................................................... 240
11.1.11 India ............................................................................................................................ 241
11.2 Market Segment Share ................................................................................................... 242
11.2.1 SPECT & SPECT/CT .................................................................................................. 242
11.2.2 PET, PET/CT & PET/MRI ............................................................................................ 243
11.3 By Geography ................................................................................................................. 245
11.3.1 Global Overview .......................................................................................................... 245
11.3.2 US ............................................................................................................................... 248
11.3.3 France ......................................................................................................................... 250
11.3.4 Germany ..................................................................................................................... 252
11.3.5 Italy ............................................................................................................................. 254
11.3.6 Spain ........................................................................................................................... 257
11.3.7 UK ............................................................................................................................... 259
11.3.8 Japan .......................................................................................................................... 261
11.3.9 Brazil ........................................................................................................................... 264
11.3.10 China .......................................................................................................................... 267
11.3.11 India ............................................................................................................................ 270
12 Appendix................................................................................................................................. 273
12.1 Abbreviations .................................................................................................................. 273
12.2 Bibliography .................................................................................................................... 278
12.3 Methodology ................................................................................................................... 309
12.3.1 Overview ..................................................................................................................... 309
12.3.2 Coverage .................................................................................................................... 309
12.3.3 Secondary Research ................................................................................................... 309
12.4 Physicians and Specialists Included in This Study .......................................................... 311
12.5 Primary Research ........................................................................................................... 312
Nuclear Imaging- PET and SPECT Equipment - Global Analysis and Market Forecasts 14 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
NUCLEAR IMAGING- PET AND SPECT EQUIPMENT - GLOBAL ANALYSIS AND MARKET FORECASTS
12.5.1 Primary Research – Key Opinion Leader Interviews.................................................... 312
12.5.2 Expert Panel Validation ............................................................................................... 313
12.5.3 Stakeholder Survey ..................................................................................................... 314
12.6 Forecasting Methodology ................................................................................................ 316
12.7 About the Authors ........................................................................................................... 317
12.7.1 Andrew Thompson, PhD, Senior Analyst ..................................................................... 317
12.7.2 Priya Radhakrishnan, MBA, Director, Medical Devices ............................................... 317
12.7.3 Bonnie Bain, PhD, Global Head of Healthcare ............................................................ 318
12.8 About GlobalData ............................................................................................................ 319
12.9 Disclaimer ....................................................................................................................... 319
1.1 List of Tables
Table 1: Applications of Nuclear Imaging .................................................................................................. 31
Table 2: FDG-PET Diagnostic Accuracy for Specific Cancers .................................................................... 32
Table 3: Potential Clinical Benefits of Hybrid Nuclear Imaging in Cardiology .............................................. 35
Table 4: Applications of PET Imaging in Non-Cancer Neurology................................................................ 36
Table 5: Applications of SPECT Imaging in Non-Cancer Neurology ........................................................... 36
Table 6: Characteristics of SPECT, PET, Ultrasound, CT, and MRI ........................................................... 41
Table 7: The Age of Canada’s Hospital-Based Medical Technology Inventories, Relative to ECCREI Rules,
2009............................................................................................................................................ 42
Table 8: Nuclear Imaging Trends in US, 2012–2020 ................................................................................. 67
Table 9: Nuclear Imaging Trends in France, 2012–2020............................................................................ 69
Table 10: Nuclear Imaging Trends in Germany, 2012–2020 ........................................................................ 72
Table 11: Nuclear Imaging Trends in Italy, 2012–2020 ................................................................................ 74
Table 12: Nuclear Imaging Trends in Spain, 2012–2020 ............................................................................. 76
Table 13: Nuclear Imaging Trends in UK, 2012–2020 ................................................................................. 79
Nuclear Imaging- PET and SPECT Equipment - Global Analysis and Market Forecasts 15 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
NUCLEAR IMAGING- PET AND SPECT EQUIPMENT - GLOBAL ANALYSIS AND MARKET FORECASTS
Table 14: Nuclear Imaging Trends in Japan, 2012–2020 ............................................................................. 81
Table 15: Nuclear Imaging Trends in Brazil, 2012–2020 .............................................................................. 84
Table 16: Nuclear Imaging Trends in China 2012-2020 ............................................................................... 87
Table 17: Nuclear Imaging Trends in India, 2012–2020 ............................................................................... 89
Table 18: Recent Device Recalls in the Nuclear Imaging Market ................................................................. 91
Table 19: Recent Key Events in the Nuclear Imaging Market ...................................................................... 93
Table 20: Nuclear Imaging Market Drivers and Barriers ............................................................................. 117
Table 21: Duplicate Diagnostic Test Incidence in France, Germany, UK, and US ...................................... 129
Table 22: Dedicated PET Scanners .......................................................................................................... 140
Table 23: Dedicated PET SWOT Analysis ................................................................................................. 141
Table 24: PET/CT Scanners ..................................................................................................................... 142
Table 25: PET/CT SWOT Analysis ............................................................................................................ 144
Table 26: PET/MRI Systems ..................................................................................................................... 146
Table 27: PET/MRI SWOT Analysis .......................................................................................................... 147
Table 28: Dedicated SPECT Systems ....................................................................................................... 149
Table 29: Dedicated SPECT SWOT Analysis ............................................................................................ 150
Table 30: SPECT/CT Systems .................................................................................................................. 153
Table 31: SPECT/CT SWOT Analysis ....................................................................................................... 154
Table 32: SPECT-Ultrasound Systems ..................................................................................................... 155
Table 33: SPECT/Ultrasound SWOT Analysis ........................................................................................... 156
Table 34: Nuclear Imaging Pipeline, 2014 ................................................................................................. 158
Table 35: CerePET SWOT Analysis .......................................................................................................... 160
Table 36: ECORAD Dual Modality Imager SWOT Analysis ....................................................................... 161
Table 37: ScintiStar PET/CT SWOT Analysis ............................................................................................ 163
Nuclear Imaging- PET and SPECT Equipment - Global Analysis and Market Forecasts 16 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
NUCLEAR IMAGING- PET AND SPECT EQUIPMENT - GLOBAL ANALYSIS AND MARKET FORECASTS
Table 38: Marginator SWOT Analysis ....................................................................................................... 164
Table 39: INSERT SPECT-MRI SWOT Analysis ....................................................................................... 167
Table 40: Nucare/Zecotek Photonics New Generation PET Scanning Device SWOT Analysis................... 168
Table 41: PET Alpha Ring Detector........................................................................................................... 169
Table 42: NeuroPET/CT Scanner SWOT Analysis .................................................................................... 170
Table 43: SynchroPET Breast PET/MRI SWOT Analysis .......................................................................... 171
Table 44: SynchroPET Wrist Scanner ....................................................................................................... 172
Table 45: SurgicEye SPECT/Ultrasound device SWOT Analysis ............................................................... 173
Table 46: Key Clinical Trials ...................................................................................................................... 175
Table 47: Company Profile – DDD-Diagnostic ........................................................................................... 178
Table 48: DDD-Diagnostic SWOT Analysis ............................................................................................... 180
Table 49: Company Profile – Digirad ......................................................................................................... 181
Table 50: Digirad SWOT Analysis ............................................................................................................. 184
Table 51: Company Profile – GE Healthcare ............................................................................................. 185
Table 52: GE Healthcare Product Portfolio ................................................................................................ 186
Table 53: GE Healthcare SWOT Analysis ................................................................................................. 189
Table 54: Company Profile – GVI Medical Devices.................................................................................... 190
Table 55: GVI Medical Devices SWOT Analysis ........................................................................................ 191
Table 56: Company Profile – Mediso Medical Imaging Systems ................................................................ 192
Table 57: Mediso Medical Imaging Systems SWOT Analysis .................................................................... 193
Table 58: Company Profile – Neurologica ................................................................................................. 194
Table 59: Neurologica SWOT Analysis ..................................................................................................... 196
Table 60: Company Profile – Neusoft Medical Systems ............................................................................. 197
Table 61: Neusoft Medical Systems SWOT Analysis ................................................................................. 199
Nuclear Imaging- PET and SPECT Equipment - Global Analysis and Market Forecasts 17 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
NUCLEAR IMAGING- PET AND SPECT EQUIPMENT - GLOBAL ANALYSIS AND MARKET FORECASTS
Table 62: Company Profile – NuCare Medical Systems ............................................................................. 200
Table 63: Nucare Medical Systems SWOT Analysis .................................................................................. 201
Table 64: Company Profile – Oncovision ................................................................................................... 202
Table 65: Oncovision SWOT Analysis ....................................................................................................... 203
Table 66: Company Profile – Philips Healthcare ........................................................................................ 204
Table 67: Philips Healthcare SWOT Analysis ............................................................................................ 210
Table 68: Company Profile – Shimadzu .................................................................................................... 211
Table 69: Shimadzu SWOT Analysis ......................................................................................................... 215
Table 70: Company Profile – Siemens Healthcare..................................................................................... 216
Table 71: Siemens Healthcare SWOT Analysis ......................................................................................... 221
Table 72: Company Profile – SurgicEye .................................................................................................... 222
Table 73: SurgicEye SWOT Analysis ........................................................................................................ 224
Table 74: Company Profile – Toshiba Medical .......................................................................................... 225
Table 75: Toshiba Medical SWOT Analysis ............................................................................................... 228
Table 76: Other Companies in the Nuclear Imaging Market, 2014 ............................................................. 229
Table 77: Global Market Value Forecast by Market Segment for SPECT & SPECT/CT (2012–2020) ......... 243
Table 78: Global Market Value Forecast by Market Segment for PET, PET/CT & PET/MRI (2012–2020) .. 244
Table 79: Global Sales of PET and SPECT Imaging Systems, 2012–2020 ................................................ 246
Table 80: United States Market Value Forecast by Market Sub-segment (2012–2020) .............................. 248
Table 81: France Market Value Forecast by Market Sub segment (2012–2020) ........................................ 250
Table 82: Germany Market Value Forecast by Market Sub segment (2012–2020) ..................................... 252
Table 83: Italy Market Value Forecast by Market Sub-segment (2012–2020)............................................. 255
Table 84: Spain Market Value Forecast by Market Sub-segment (2012–2020) .......................................... 257
Table 85: UK Market Value Forecast by Market Sub-segment (2012–2020) .............................................. 259
Nuclear Imaging- PET and SPECT Equipment - Global Analysis and Market Forecasts 18 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
NUCLEAR IMAGING- PET AND SPECT EQUIPMENT - GLOBAL ANALYSIS AND MARKET FORECASTS
Table 86: Japan Market Value Forecast by Market Sub-segment (2012–2020).......................................... 262
Table 87: Brazil Market Value Forecast by Market Sub-segment (2012–2020) .......................................... 264
Table 88: China Market Value Forecast by Market Sub-segment (2012–2020) .......................................... 267
Table 89: India Market Value Forecast by Market Sub-segment (2012–2020) ........................................... 270
Table 90: Primary Research Summary ...................................................................................................... 314
Table 91: Primary Research Participants Affiliation ................................................................................... 315
1.2 List of Figures
Figure 1: Cyclotron Distribution in 10 Countries .......................................................................................... 24
Figure 2: Localization of Tumor in Chest Cavity by PET, CT, and PET/CT .................................................. 28
Figure 3: Mutually Beneficial Effects of PET/MRI Imaging........................................................................... 30
Figure 4: Nuclear Imaging Trends in US, 2012–2020 ................................................................................. 66
Figure 5: Nuclear Imaging Trends in France, 2012–2020............................................................................ 69
Figure 6: Nuclear Imaging Trends in Germany, 2012–2020 ........................................................................ 72
Figure 7: Nuclear Imaging Trends in Italy, 2012–2020 ................................................................................ 74
Figure 8: Nuclear Imaging Trends in Spain, 2012–2020 ............................................................................. 76
Figure 9: Nuclear Imaging Trends in UK, 2012–2020 ................................................................................. 79
Figure 10: Nuclear Imaging Trends in Japan, 2012–2020 ............................................................................. 81
Figure 11: Nuclear Imaging Trends in Brazil, 2012–2020 .............................................................................. 84
Figure 12: Nuclear Imaging Trends in China, 2012–2020 ............................................................................. 86
Figure 13: SPECT and PET Imaging Trends in India, 2012–2020 ................................................................. 89
Figure 14: Total Medicare Expenditures for Imaging Services Paid Under the Physician Fee Schedule, 2000–
2006............................................................................................................................................ 95
Figure 15: Imaging Utilization Rates (Number of Outpatient Visits with MRI/CT per 1,000 Persons), by Year in
the US ....................................................................................................................................... 118
Nuclear Imaging- PET and SPECT Equipment - Global Analysis and Market Forecasts 19 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
NUCLEAR IMAGING- PET AND SPECT EQUIPMENT - GLOBAL ANALYSIS AND MARKET FORECASTS
Figure 16: Global Company Market Shares for Nuclear Imaging Equipment (2012) .................................... 232
Figure 17: US Company Market Shares for Nuclear Imaging Equipment (2012) ......................................... 233
Figure 18: France Company Market Shares for Nuclear Imaging Equipment (2012) ................................... 234
Figure 19: Germany Company Market Shares for Nuclear Imaging Equipment (2012) ................................ 235
Figure 20: Italy Company Market Shares for Nuclear Imaging Equipment (2012) ........................................ 236
Figure 21: Spain Company Market Shares for Nuclear Imaging Equipment (2012) ..................................... 237
Figure 22: UK Company Market Shares for Nuclear Imaging Equipment (2012) ......................................... 238
Figure 23: Japan Company Market Shares for Nuclear Imaging Equipment (2012) ..................................... 239
Figure 24: Brazil Company Market Shares for Nuclear Imaging Equipment (2012) ..................................... 240
Figure 25: China Company Market Shares for Nuclear Imaging Equipment (2012) ..................................... 241
Figure 26: India Company Market Shares for Nuclear Imaging Equipment (2012) ....................................... 242
Figure 27: Global Market Value Forecast by Market Segment for SPECT & SPECT/CT (2012–2020) ......... 243
Figure 28: Global Market Value Forecast by Market Segment for PET, PET/CT, and PET/MRI (2012–2020)
................................................................................................................................................. 245
Figure 29: Global Sales of PET and SPECT Imaging Systems, 2012–2020 ................................................ 246
Figure 30: Global Market Share of Nuclear Imaging, 2012 and 2020 .......................................................... 247
Figure 31: United States Market Value Forecast by Market Sub-segment (2012–2020) .............................. 249
Figure 32: France Market Value Forecast by Market Subsegment (2012–2020) ......................................... 251
Figure 33: Germany Market Value Forecast by Market Sub segment (2012–2020) ..................................... 253
Figure 34: Italy Market Value Forecast by Market Sub segment (2012–2020) ............................................. 255
Figure 35: Spain Market Value Forecast by Market Sub-segment (2012–2020) .......................................... 258
Figure 36: UK Market Value Forecast by Market Sub-segment (2012–2020) .............................................. 260
Figure 37: Japan Market Value Forecast by Market Sub segment (2012–2020) .......................................... 262
Figure 38: Brazil Market Value Forecast by Market Sub segment (2012–2020) .......................................... 265
Figure 39: China Market Value Forecast by Market Sub-segment (2012–2020) .......................................... 268
Nuclear Imaging- PET and SPECT Equipment - Global Analysis and Market Forecasts 20 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
NUCLEAR IMAGING- PET AND SPECT EQUIPMENT - GLOBAL ANALYSIS AND MARKET FORECASTS
Figure 40: India Market Value Forecast by Market Sub segment (2012–2020) ............................................ 271
Figure 41: Primary Research Summary ...................................................................................................... 314
Figure 42: Primary Research Participants Affiliation ................................................................................... 315
Nuclear Imaging- PET and SPECT Equipment - Global Analysis and Market Forecasts 21 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
NUCLEAR IMAGING- PET AND SPECT EQUIPMENT - GLOBAL ANALYSIS AND MARKET FORECASTS
Introduction
2 Introduction
An early diagnosis of disease is the foundation of increasing survival rates. Single-photon emission
computed tomography (SPECT) and positron emission tomography (PET) imaging are diagnostic
imaging techniques that are widely used in a variety of disease areas including oncology,
cardiovascular disease, bone disease, and infectious disease. This report provides an analysis of
the nuclear imaging market, with a particular focus on SPECT and PET imaging and hybrid
modalities within the US, the 5EU (France, Germany, Italy, Spain, and UK), Brazil, and the Asia-
Pacific (APAC) region (Japan, China, and India). This report identifies the drivers and barriers to
nuclear imaging, as well as unmet needs in this market. This report also discusses physician
attitudes towards current diagnostic nuclear imaging modalities, and the future of nuclear imaging
in the face of rapid technological advancement and an increasingly challenging reimbursement
environment.
2.1 Catalyst
PET and SPECT imaging are well-established techniques in the nuclear imaging market. The
advent of hybrid imaging has enabled PET/CT imaging to undergo explosive growth, but this has
increased demand on struggling healthcare budgets. New developments in hybrid nuclear imaging
promise to further increase the utility of these technologies, while significantly improving patient
cost savings and safety by reducing the repeated or examinations. However, these improvements
come with a significant increase in the capital cost of equipment. This report examines how new
technologies can emerge in the face of healthcare reform and other economic pressures that may
affect the demand for nuclear imaging. Further, it focuses on the industry trends, promising pipeline
products, and competitive landscape of nuclear imaging.
Nuclear Imaging- PET and SPECT Equipment - Global Analysis and Market Forecasts 22 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
NUCLEAR IMAGING- PET AND SPECT EQUIPMENT - GLOBAL ANALYSIS AND MARKET FORECASTS
Introduction
2.2 Related Reports
GlobalData (2013). MediFocus: Future of Molecular Imaging, August, 2013, GDME002MFR.
GlobalData (2013). MediPoint: Breast Cancer Imaging – Global Analysis and Market
Forecasts, May, 2013, GDME0166MAR.
GlobalData (2014). MediPoint: Diagnostic Ultrasound Imaging - Global Analysis and Market
Forecasts, January 2014, GDME0182MAR.
GlobalData (2014). MediPoint: Diagnostic X-ray Imaging - Global Analysis and Market
Forecasts, July 2014, GDME0203MAR.
Nuclear Imaging- PET and SPECT Equipment - Global Analysis and Market Forecasts 319 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Appendix
NUCLEAR IMAGING- PET AND SPECT EQUIPMENT - GLOBAL ANALYSIS AND MARKET FORECASTS
12.8 About GlobalData
GlobalData is a leading global provider of business intelligence in the Healthcare industry.
GlobalData provides its clients with up-to-date information and analysis on the latest developments
in drug research, disease analysis, and clinical research and development. Our integrated business
intelligence solutions include a range of interactive online databases, analytical tools, reports and
forecasts. Our analysis is supported by a 24/7 client support and analyst team.
GlobalData has offices in New York, San Francisco, Boston, London, India, Korea, Japan,
Singapore, and Australia.
12.9 Disclaimer
All Rights Reserved.
No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any
form by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior
permission of the publisher, GlobalData.